Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Self-assembling nanoparticles encapsulating zoledronic acid inhibit mesenchymal stromal cells differentiation, migration and secretion of proangiogenic factors and their interactions with prostate cancer cells

C. Borghese, N. Casagrande, E. Pivetta, A. Colombatti, M. Boccellino, E. Amler, N. Normanno, M. Caraglia, G. De Rosa, D. Aldinucci,

. 2017 ; 8 (26) : 42926-42938.

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc18025042

Zoledronic Acid (ZA) rapidly concentrates into the bone and reduces skeletal-related events and pain in bone metastatic prostate cancer (PCa), but exerts only a limited or absent impact as anti-cancer activity. Recently, we developed self-assembling nanoparticles (NPS) encapsulating zoledronic acid (NZ) that allowed a higher intratumor delivery of the drug compared with free zoledronic acid (ZA) in in vivo cancer models of PCa. Increasing evidence suggests that Bone Marrow (BM) Mesenchymal stromal cells (BM-MSCs) are recruited into the stroma of developing tumors where they contribute to progression by enhancing tumor growth and metastasis.We demonstrated that treatment with NZ decreased migration and differentiation into adipocytes and osteoblasts of MSCs and inhibited osteoclastogenesis. Treatment with NZ reduced the capability of MSCs to promote the migration and the clonogenic growth of the prostate cancer cell lines PC3 and DU145. The levels of Interleukin-6 and of the pro-angiogenic factors VEGF and FGF-2 were significantly reduced in MSC-CM derived from MSCs treated with NZ, and CCL5 secretion was almost totally abolished. Moreover, treatment of MSCs with supernatants from PC3 cells, leading to tumor-educated MSCs (TE-MSCs), increased the secretion of IL-6, CCL5, VEGF and FGF-2 by MSCs and increased their capability to increase PC3 cells clonogenic growth. Treatment with NZ decreased cytokine secretion and the pro-tumorigenic effects also of TE-MSCS. In conclusion, demonstrating that NZ is capable to inhibit the cross talk between MSCs and PCa, this study provides a novel insight to explain the powerful anticancer activity of NZ on PCa.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18025042
003      
CZ-PrNML
005      
20180710092823.0
007      
ta
008      
180709s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.18632/oncotarget.17216 $2 doi
035    __
$a (PubMed)28477013
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Borghese, Cinzia $u Molecular Oncology Unit, Centro di Riferimento Oncologico, IRCCS-National Cancer Institute, Aviano, PN, Italy.
245    10
$a Self-assembling nanoparticles encapsulating zoledronic acid inhibit mesenchymal stromal cells differentiation, migration and secretion of proangiogenic factors and their interactions with prostate cancer cells / $c C. Borghese, N. Casagrande, E. Pivetta, A. Colombatti, M. Boccellino, E. Amler, N. Normanno, M. Caraglia, G. De Rosa, D. Aldinucci,
520    9_
$a Zoledronic Acid (ZA) rapidly concentrates into the bone and reduces skeletal-related events and pain in bone metastatic prostate cancer (PCa), but exerts only a limited or absent impact as anti-cancer activity. Recently, we developed self-assembling nanoparticles (NPS) encapsulating zoledronic acid (NZ) that allowed a higher intratumor delivery of the drug compared with free zoledronic acid (ZA) in in vivo cancer models of PCa. Increasing evidence suggests that Bone Marrow (BM) Mesenchymal stromal cells (BM-MSCs) are recruited into the stroma of developing tumors where they contribute to progression by enhancing tumor growth and metastasis.We demonstrated that treatment with NZ decreased migration and differentiation into adipocytes and osteoblasts of MSCs and inhibited osteoclastogenesis. Treatment with NZ reduced the capability of MSCs to promote the migration and the clonogenic growth of the prostate cancer cell lines PC3 and DU145. The levels of Interleukin-6 and of the pro-angiogenic factors VEGF and FGF-2 were significantly reduced in MSC-CM derived from MSCs treated with NZ, and CCL5 secretion was almost totally abolished. Moreover, treatment of MSCs with supernatants from PC3 cells, leading to tumor-educated MSCs (TE-MSCs), increased the secretion of IL-6, CCL5, VEGF and FGF-2 by MSCs and increased their capability to increase PC3 cells clonogenic growth. Treatment with NZ decreased cytokine secretion and the pro-tumorigenic effects also of TE-MSCS. In conclusion, demonstrating that NZ is capable to inhibit the cross talk between MSCs and PCa, this study provides a novel insight to explain the powerful anticancer activity of NZ on PCa.
650    _2
$a tukové buňky $x cytologie $x účinky léků $x metabolismus $7 D017667
650    _2
$a látky indukující angiogenezi $x metabolismus $7 D043925
650    _2
$a mezibuněčná komunikace $x účinky léků $7 D002450
650    _2
$a buněčná diferenciace $x účinky léků $7 D002454
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a pohyb buněk $x účinky léků $7 D002465
650    _2
$a viabilita buněk $x účinky léků $7 D002470
650    _2
$a cytokiny $x metabolismus $7 D016207
650    _2
$a bisfosfonáty $x aplikace a dávkování $7 D004164
650    _2
$a lidé $7 D006801
650    _2
$a imidazoly $x aplikace a dávkování $7 D007093
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a mezenchymální kmenové buňky $x cytologie $x účinky léků $x metabolismus $7 D059630
650    _2
$a nanočástice $7 D053758
650    _2
$a osteoblasty $x cytologie $x účinky léků $x metabolismus $7 D010006
650    _2
$a osteoklasty $x cytologie $x účinky léků $x metabolismus $7 D010010
650    _2
$a nádory prostaty $x metabolismus $x patologie $7 D011471
650    _2
$a nádorové mikroprostředí $x účinky léků $7 D059016
655    _2
$a časopisecké články $7 D016428
700    1_
$a Casagrande, Naike $u Molecular Oncology Unit, Centro di Riferimento Oncologico, IRCCS-National Cancer Institute, Aviano, PN, Italy.
700    1_
$a Pivetta, Eliana $u Molecular Oncology Unit, Centro di Riferimento Oncologico, IRCCS-National Cancer Institute, Aviano, PN, Italy.
700    1_
$a Colombatti, Alfonso $u Molecular Oncology Unit, Centro di Riferimento Oncologico, IRCCS-National Cancer Institute, Aviano, PN, Italy.
700    1_
$a Boccellino, Mariarosaria $u Department of Biochemistry, Biophysics and General Pathology, Second University of Naples, Naples, Italy. Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA, USA.
700    1_
$a Amler, Evzen $u Indoor Environmental Quality, University Center for Energy Efficient Buildings, Czech Technical University in Prague, Buštěhrad, Czech Republic. Laboratory of Tissue Engineering, Institute of Experimental Medicine, Czech Academy of Sciences, Prague, Czech Republic.
700    1_
$a Normanno, Nicola $u Cell Biology & Biotherapy Unit, Istituto Nazionale Tumori "Fondazione G Pascale"-IRCCS, Naples, Italy.
700    1_
$a Caraglia, Michele $u Department of Biochemistry, Biophysics and General Pathology, Second University of Naples, Naples, Italy. Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA, USA.
700    1_
$a De Rosa, Giuseppe $u Department of Pharmacy, Federico II University of Naples, Naples, Italy.
700    1_
$a Aldinucci, Donatella $u Molecular Oncology Unit, Centro di Riferimento Oncologico, IRCCS-National Cancer Institute, Aviano, PN, Italy.
773    0_
$w MED00184852 $t Oncotarget $x 1949-2553 $g Roč. 8, č. 26 (2017), s. 42926-42938
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28477013 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180709 $b ABA008
991    __
$a 20180710093113 $b ABA008
999    __
$a ok $b bmc $g 1317173 $s 1021963
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 8 $c 26 $d 42926-42938 $i 1949-2553 $m Oncotarget $n Oncotarget $x MED00184852
LZP    __
$a Pubmed-20180709

Find record

Citation metrics

Archiving options